<?xml version='1.0' encoding='utf-8'?>
<document id="15760430"><sentence text="Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia."><entity charOffset="108-116" id="DDI-PubMed.15760430.s1.e0" text="amikacin" /></sentence><sentence text="A guinea-pig pneumonia model involving imipenem-susceptible and imipenem-resistant strains of Acinetobacter baumannii was developed to assess the in-vitro and in-vivo activities of imipenem, alone or in combination with amikacin, and the pharmacokinetic and pharmacodynamic parameters"><entity charOffset="39-47" id="DDI-PubMed.15760430.s2.e0" text="imipenem" /><entity charOffset="64-72" id="DDI-PubMed.15760430.s2.e1" text="imipenem" /><entity charOffset="181-189" id="DDI-PubMed.15760430.s2.e2" text="imipenem" /><entity charOffset="220-228" id="DDI-PubMed.15760430.s2.e3" text="amikacin" /><pair ddi="false" e1="DDI-PubMed.15760430.s2.e0" e2="DDI-PubMed.15760430.s2.e0" /><pair ddi="false" e1="DDI-PubMed.15760430.s2.e0" e2="DDI-PubMed.15760430.s2.e1" /><pair ddi="false" e1="DDI-PubMed.15760430.s2.e0" e2="DDI-PubMed.15760430.s2.e2" /><pair ddi="false" e1="DDI-PubMed.15760430.s2.e0" e2="DDI-PubMed.15760430.s2.e3" /><pair ddi="false" e1="DDI-PubMed.15760430.s2.e1" e2="DDI-PubMed.15760430.s2.e1" /><pair ddi="false" e1="DDI-PubMed.15760430.s2.e1" e2="DDI-PubMed.15760430.s2.e2" /><pair ddi="false" e1="DDI-PubMed.15760430.s2.e1" e2="DDI-PubMed.15760430.s2.e3" /><pair ddi="false" e1="DDI-PubMed.15760430.s2.e2" e2="DDI-PubMed.15760430.s2.e2" /><pair ddi="false" e1="DDI-PubMed.15760430.s2.e2" e2="DDI-PubMed.15760430.s2.e3" /></sentence><sentence text=" Serum levels were measured by bioassay (imipenem) or immunoassay (amikacin), followed by calculation of pharmacokinetic and pharmacodynamic parameters (Cmax, AUC, t1/2, Cmax/MIC, AUC/MIC, and Deltat/MIC)"><entity charOffset="41-49" id="DDI-PubMed.15760430.s3.e0" text="imipenem" /><entity charOffset="67-75" id="DDI-PubMed.15760430.s3.e1" text="amikacin" /><pair ddi="false" e1="DDI-PubMed.15760430.s3.e0" e2="DDI-PubMed.15760430.s3.e0" /><pair ddi="false" e1="DDI-PubMed.15760430.s3.e0" e2="DDI-PubMed.15760430.s3.e1" /></sentence><sentence text=" In-vivo efficacy was evaluated by comparing bacterial counts in the lungs of treatment groups with end-of-therapy controls by anova and post-hoc tests" /><sentence text=" Decreases in the Cmax (13" /><sentence text="4%), AUC (13%), t1/2 (25%) and Deltat/MIC (11" /><sentence text="8-32" /><sentence text="2%) of imipenem were observed when it was administered with amikacin, compared with administration of imipenem alone"><entity charOffset="7-15" id="DDI-PubMed.15760430.s8.e0" text="imipenem" /><entity charOffset="60-68" id="DDI-PubMed.15760430.s8.e1" text="amikacin" /><entity charOffset="102-110" id="DDI-PubMed.15760430.s8.e2" text="imipenem" /><pair ddi="false" e1="DDI-PubMed.15760430.s8.e0" e2="DDI-PubMed.15760430.s8.e0" /><pair ddi="false" e1="DDI-PubMed.15760430.s8.e0" e2="DDI-PubMed.15760430.s8.e1" /><pair ddi="false" e1="DDI-PubMed.15760430.s8.e0" e2="DDI-PubMed.15760430.s8.e2" /><pair ddi="false" e1="DDI-PubMed.15760430.s8.e1" e2="DDI-PubMed.15760430.s8.e1" /><pair ddi="false" e1="DDI-PubMed.15760430.s8.e1" e2="DDI-PubMed.15760430.s8.e2" /></sentence><sentence text=" Similarly, decreases in the Cmax (34" /><sentence text="5%), AUC (11" /><sentence text="6%), Cmax/MIC (34" /><sentence text="5%) and AUC/MIC (11" /><sentence text="7%) of amikacin were observed when it was administered with imipenem"><entity charOffset="7-15" id="DDI-PubMed.15760430.s13.e0" text="amikacin" /><entity charOffset="60-68" id="DDI-PubMed.15760430.s13.e1" text="imipenem" /><pair ddi="false" e1="DDI-PubMed.15760430.s13.e0" e2="DDI-PubMed.15760430.s13.e0" /><pair ddi="false" e1="DDI-PubMed.15760430.s13.e0" e2="DDI-PubMed.15760430.s13.e1" /></sentence><sentence text=" Bacterial counts in lungs were reduced by imipenem (p 0"><entity charOffset="43-51" id="DDI-PubMed.15760430.s14.e0" text="imipenem" /></sentence><sentence text="004) with the imipenem-susceptible strain, and by amikacin (p 0"><entity charOffset="14-22" id="DDI-PubMed.15760430.s15.e0" text="imipenem" /><entity charOffset="50-58" id="DDI-PubMed.15760430.s15.e1" text="amikacin" /><pair ddi="false" e1="DDI-PubMed.15760430.s15.e0" e2="DDI-PubMed.15760430.s15.e0" /><pair ddi="false" e1="DDI-PubMed.15760430.s15.e0" e2="DDI-PubMed.15760430.s15.e1" /></sentence><sentence text="001) with the imipenem-resistant strain"><entity charOffset="14-22" id="DDI-PubMed.15760430.s16.e0" text="imipenem" /></sentence><sentence text=" The combination of imipenem plus amikacin was inferior to imipenem alone with the imipenem-susceptible strain (p 0"><entity charOffset="20-28" id="DDI-PubMed.15760430.s17.e0" text="imipenem" /><entity charOffset="34-42" id="DDI-PubMed.15760430.s17.e1" text="amikacin" /><entity charOffset="59-67" id="DDI-PubMed.15760430.s17.e2" text="imipenem" /><entity charOffset="83-91" id="DDI-PubMed.15760430.s17.e3" text="imipenem" /><pair ddi="false" e1="DDI-PubMed.15760430.s17.e0" e2="DDI-PubMed.15760430.s17.e0" /><pair ddi="false" e1="DDI-PubMed.15760430.s17.e0" e2="DDI-PubMed.15760430.s17.e1" /><pair ddi="false" e1="DDI-PubMed.15760430.s17.e0" e2="DDI-PubMed.15760430.s17.e2" /><pair ddi="false" e1="DDI-PubMed.15760430.s17.e0" e2="DDI-PubMed.15760430.s17.e3" /><pair ddi="false" e1="DDI-PubMed.15760430.s17.e1" e2="DDI-PubMed.15760430.s17.e1" /><pair ddi="false" e1="DDI-PubMed.15760430.s17.e1" e2="DDI-PubMed.15760430.s17.e2" /><pair ddi="false" e1="DDI-PubMed.15760430.s17.e1" e2="DDI-PubMed.15760430.s17.e3" /><pair ddi="false" e1="DDI-PubMed.15760430.s17.e2" e2="DDI-PubMed.15760430.s17.e2" /><pair ddi="false" e1="DDI-PubMed.15760430.s17.e2" e2="DDI-PubMed.15760430.s17.e3" /></sentence><sentence text="01), despite their in-vitro synergy, and was inferior to amikacin alone with the imipenem-resistant strain (p &lt; 0"><entity charOffset="57-65" id="DDI-PubMed.15760430.s18.e0" text="amikacin" /><entity charOffset="81-89" id="DDI-PubMed.15760430.s18.e1" text="imipenem" /><pair ddi="false" e1="DDI-PubMed.15760430.s18.e0" e2="DDI-PubMed.15760430.s18.e0" /><pair ddi="false" e1="DDI-PubMed.15760430.s18.e0" e2="DDI-PubMed.15760430.s18.e1" /></sentence><sentence text="0001)" /><sentence text=" In summary, combined use of imipenem with amikacin was less efficacious than monotherapy, probably because of a drug-drug interaction that resulted in decreased pharmacokinetic and pharmacodynamic parameters for both antimicrobial agents"><entity charOffset="29-37" id="DDI-PubMed.15760430.s20.e0" text="imipenem" /><entity charOffset="43-51" id="DDI-PubMed.15760430.s20.e1" text="amikacin" /><pair ddi="false" e1="DDI-PubMed.15760430.s20.e0" e2="DDI-PubMed.15760430.s20.e0" /><pair ddi="false" e1="DDI-PubMed.15760430.s20.e0" e2="DDI-PubMed.15760430.s20.e1" /></sentence><sentence text="" /></document>